Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

被引：0

作者：

Pietro Lampertico

Stefan Mauss

Marcello Persico

Stephen T. Barclay

Steven Marx

Kristina Lohmann

Mark Bondin

ZhenZhen Zhang

Fiona Marra

Pamela S. Belperio

Heiner Wedemeyer

Steven Flamm

机构：

[1] Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico,Division of Gastroenterology and Hepatolgy, CRC “A.M. and A.Migliavacca” Center for Liver Disease

[2] University of Milan,Department of Pathophysiology and Transplantation

[3] Center for HIV and Hepatogastroenterology,Internal Medicine and Hepatology Unit

[4] University of Salerno,Department of Life Sciences

[5] Glasgow Caledonian University,Department of Veterans Affairs

[6] Gastroenterology,Department of Gastroenterology and Hepatology

[7] Glasgow Royal Infirmary,Department of Gastroenterology, Hepatology and Endocrinology

[8] AbbVie Inc.,undefined

[9] AbbVie Deutschland GmBH Co. KG,undefined

[10] University of Liverpool Hepatology Drug Interactions Group,undefined

[11] VA Palo Alto Healthcare System,undefined

[12] Essen University Hospital,undefined

[13] Leberstiftungs-GmbH Deutschland,undefined

[14] Hannover Medical School,undefined

[15] Northwestern University Feinberg School of Medicine,undefined

来源：

Advances in Therapy | 2020年 / 37卷

关键词：

Fibrosis; Hepatitis C; Infectious disease; Review; Therapeutics;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：4033 / 4042

页数：9

共 50 条

[21] Preliminary Efficacy and Safety of 8-Week Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1-6 Infection and Compensated Cirrhosis: The Expedition-8 Study
Brown, Robert S., Jr.
Hezode, Christophe
Wang, Stanley
Buti, Maria
Chuang, Wan-Long
Aguilar, Humberto I.
Horvath, Gabor
Rosado-Carrion, Barbara
Rodriguez-Perez, Federico
Cohen, Eric
Hui, Yiran B.
Schnell, Gretja
Lin, Chih-Wei
Rodrigues, Lino, Jr.
Trinh, Roger
Mensa, Federico J.
Felizarta, Franco
HEPATOLOGY, 2018, 68 : 425A - 426A
[22] Management of treatment-naïve diabetic macular edema patients: Review of real-world clinical data
Boscia, Francesco
Veritti, Daniele
Iaculli, Cristiana
Lattanzio, Rosangela
Freda, Simona
Piergentili, Benedetta
Varano, Monica
EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2024, 34 (06) : 1675 - 1694
[23] PRELIMINARY EFFICACY AND SAFETY OF 8-WEEK GLECAPREVIR/PIBRENTASVIR IN PATIENTS WITH HCV GENOTYPE 1-6 INFECTION AND COMPENSATED CIRRHOSIS: THE EXPEDITION-8 STUDY
Brown, Robert S., Jr.
Hezode, Christopher
Wang, Stanley
Buti, Maria
Chuang, Wan-Long
Aguilar, Humberto
Horvath, Gabor
Carrion, Barbara Rosado
Rodriguez-Perez, Federico
Cohen, Eric
Hu, Yiran B.
Schnell, Gretja
Lin, Chih-Wei
Rodrigues, Lino
Trinh, Roger
Mensa, Federico J.
GUT, 2019, 68 : A146 - A146
[24] Preliminary Efficacy and Safety of 8-Week Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1-6 Infection and Compensated Cirrhosis: The Expedition-8 Study
Brown, Robert S., Jr.
Hezode, Christophe
Wang, Stanley
Buti, Maria
Chuang, Wan-Long
Aguilar, Humberto I.
Horvath, Gabor
Rosado-Carrion, Barbara
Rodriguez-Perez, Federico
Cohen, Eric
Hu, Yiran B.
Schnell, Gretja
Lin, Chih-Wei
Rodrigues, Lino, Jr.
Trinh, Roger
Mensa, Federico J.
Felizarta, Franco
HEPATOLOGY, 2018, 68 (06) : 1450A - 1451A
[25] Real-World Data on the Use of Glecaprevir/Pibrentasvir in the Treatment of Hepatitis C: Is Shorter Treatment Possible?
Tuzun, Ahmet Yekta
Mermutluoglu, Cigdem
Celen, Mustafa Kemal
VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, 2024, 30 (02): : 36 - 40
[26] Efficacy of Real-world Entecavir Therapy in Treatment-na?ve Chronic Hepatitis B Patients
Xie Yan-Di
Ma Hui
Feng Bo
Wei Lai
中华医学杂志英文版, 2017, 130 (18) : 2190 - 2197
[27] Glecaprevir/Pibrentasvir: The First 8-Week, Pangenotypic HCV Treatment Regimen for Patients 12 Years of Age and Older
Huff, Jamie
Andersen, Rebecca
ANNALS OF PHARMACOTHERAPY, 2020, 54 (03) : 262 - 276
[28] Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naive noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan
Ikeda, Hiroki
Watanabe, Tsunamasa
Atsukawa, Masanori
Toyoda, Hidenori
Takaguchi, Koichi
Nakamuta, Makoto
Matsumoto, Nobuyuki
Okuse, Chiaki
Tada, Toshifumi
Tsutsui, Akemi
Yamashita, Naoki
Kondo, Chisa
Hayama, Korenobu
Kato, Keizo
Itokawa, Norio
Arai, Taeang
Shimada, Noritomo
Asano, Toru
Uojima, Haruki
Ogawa, Chikara
Mikami, Shigeru
Ikegami, Tadashi
Fukunishi, Shinya
Asai, Akira
Iio, Etsuko
Tsubota, Akihito
Hiraoka, Atsushi
Nozaki, Akito
Okubo, Hironao
Tachi, Yoshihiko
Moriya, Akio
Oikawa, Tsunekazu
Matsumoto, Yoshihiro
Tsuruoka, Shuichi
Tani, Joji
Kikuchi, Kan
Iwakiri, Katsuhiko
Tanaka, Yasuhito
Kumada, Takashi
JOURNAL OF VIRAL HEPATITIS, 2019, 26 (11) : 1266 - 1275
[29] EVALUATION OF 8-WEEK GLECAPREVIR/PIBRENTASVIR TREATMENT IN DIRECT-ACTING ANTIVIRAL-NAIVE NON-CIRRHOTIC GENOTYPE 1 AND 2 HCV PATIENTS IN A REAL-WORLD SETTING IN JAPAN
Ehira, Takuya
Watanabe, Tsunamasa
Hiroki, Ikeda
Hattori, Nobuhiro
Matsunaga, Kotaro
Matsumoto, Nobuyuki
Okuse, Chiaki
Nozaki, Akito
Uojima, Haruki
Asano, Toru
Mikami, Shigeru
Ikegami, Tadashi
Abe, Hiroshi
Kato, Keizo
Tsubota, Akihito
Itoh, Fumio
HEPATOLOGY, 2019, 70 : 952A - 953A
[30] The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort
Yaras, Serkan
Demir, Mehmet
Barutcu, Sezgin
Yildirim, Abdullah Emre
Gurel, Selim
Ucbilek, Enver
Kurtulmus, Ilkce Akgun
Kayhan, Meral Akdogan
Vatansever, Sezgin
Adanir, Haydar
Danis, Nilay
Duman, Serkan
Turan, Ilker
Ari, Derya
Kose, Sukran
Alkim, Huseyin
Harputluoglu, Muhsin Murat
Dilber, Feyza
Akyildiz, Murat
Cosar, Arif Mansur
Durak, Serdar
Sirin, Goktug
Kefeli, Ayse
Gokcan, Hale
Avcioglu, Ufuk
Ayyildiz, Talat
Sezgin, Orhan
Akarsu, Mesut
Dincer, Dinc
Guzelbulut, Fatih
Gunsar, Fulya
Akarca, Ulus Salih
Idilman, Ramazan
HEPATOLOGY FORUM, 2023, 4 (03): : 92 - 96

← 1 2 3 4 5 →